Prolias Launches Family Of Cardiovascular Based ProSpectrum LigandsTM

Main Category: Cardiovascular / Cardiology
Also Included In: Heart Disease
Article Date: 20 Aug 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

Prolias, a biotechnology company using proprietary Bead BlotTM technology to develop ligand-based affinity resins that purify and target proteins and protein complexes, announced that it has launched its first family of ProSpectrum LigandsTM. These ligands are focused on cardiovascular disease, with ligands that bind High-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), and cardiac Troponin I proteins.

The proprietary ProSpectrum LigandsTM utilize chemically synthesized peptide ligands on microscopic chromatography resin. Synthesis protocols enable controlled synthesis of identical peptide ligands, thereby increasing reproducibility performance. Chemical peptide ligands rival antibodies for selectivity and specificity, with lower cost and more reproducible production.

ProSpectrum LigandsTM provide a robust matrix that allows scientists and researchers to bind, and purify, specifically targeted proteins and physiological protein complexes from complex biological sources, including whole blood, plasma and serum.

Source
Prolias

• Additional
• References
• Citations